On Tuesday, C4 Therapeutics Inc (NASDAQ: CCCC) was 5.98% up from the session before settling in for the closing price of $2.34. A 52-week range for CCCC has been $1.09 – $6.20.
A company in the Healthcare sector has dropped its sales by -8.92% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 3.73%. With a float of $69.27 million, this company’s outstanding shares have now reached $74.17 million.
C4 Therapeutics Inc (CCCC) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward C4 Therapeutics Inc stocks. The insider ownership of C4 Therapeutics Inc is 28.52%, while institutional ownership is 58.18%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.49 earnings per share (EPS) during the time that was less than consensus figure (set at -0.45) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.73% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.64% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
You can see what C4 Therapeutics Inc (CCCC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.67, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.41 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Let’s dig in a bit further. During the last 5-days, its volume was 1.02 million. That was inferior than the volume of 1.58 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 44.58%.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 48.91%, which indicates a significant decrease from 50.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.18 in the past 14 days, which was lower than the 0.23 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.51, while its 200-day Moving Average is $2.16. However, in the short run, C4 Therapeutics Inc’s stock first resistance to watch stands at $2.54. Second resistance stands at $2.59. The third major resistance level sits at $2.70. If the price goes on to break the first support level at $2.37, it is likely to go to the next support level at $2.26. The third support level lies at $2.21 if the price breaches the second support level.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
There are 71,171K outstanding shares of the company, which has a market capitalization of 240.35 million. As of now, sales total 35,580 K while income totals -105,320 K. Its latest quarter income was 11,230 K while its last quarter net income were -32,170 K.
